Cagrilintide
aka NN9838
GLP-1 / Metabolic
Mechanism
Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk. It is investigational and not FDA-approved; Novo Nordisk's lead development path is the CagriSema co-formulation with semaglutide for weight management. Monotherapy cagrilintide was evaluated in Phase 2 but was deprioritized in favor of the combination.
Identification
Vendors selling Cagrilintide
No vendor listings on file yet.
Research
No citations on file yet.